NP / PA
Mercy Health-Lourdes Hospital LLC
Mercy Health-Lourdes Hospital LLC was paid $61.89M by Medicaid between Jan 2018 and Dec 2024, across 444 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoMERCY HEALTH-LOURDES HOSPITAL LLC
PADUCAH, KY 42003
PADUCAH, KY 42003
33aNPI1346244126assigned 06/09/2005
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$61.89M
24GClaims1,524,507
24DCodes billed444
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in Kentucky
Rank by total paid#1 of 53
Median peer was paid$84K
This provider vs. median741×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 206,311 | $7.25M | |
| 2019 | 229,107 | $9.09M | |
| 2020 | 200,622 | $7.45M | |
| 2021 | 235,231 | $8.58M | |
| 2022 | 237,020 | $10.04M | |
| 2023 | 230,811 | $9.95M | |
| 2024incomplete | 185,405 | $9.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 25,229 | 19,549 | $6.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 17,616 | 12,027 | $5.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 27,714 | 23,423 | $5.00M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.6% | 9,067 | 8,123 | $2.87M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 8,521 | 7,066 | $2.65M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 48,889 | 19,034 | $2.13M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 9,071 | 7,052 | $1.35M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.2% | 6,092 | 2,540 | $1.34M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 22,793 | 13,786 | $1.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 11,500 | 9,814 | $1.28M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 17,757 | 5,492 | $1.10M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.7% | 2,437 | 1,585 | $1.06M |
432 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 3,916 | $921K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 14,311 | $863K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 2,524 | $834K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 3,170 | $799K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 7,153 | $769K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 13,700 | $752K |
| 97597 | 1.2% | 5,339 | $733K | |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 12,559 | $720K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 6,406 | $690K |
| 36415 | Collection of venous blood by venipuncture | <1% | 181,701 | $524K |
| 80053 | Comprehensive metabolic panel | <1% | 76,989 | $514K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,255 | $507K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,696 | $503K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,642 | $488K |
| 20553 | <1% | 3,202 | $452K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,393 | $444K |
| 20611 | <1% | 2,510 | $399K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,592 | $392K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,697 | $389K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,206 | $383K |
| 93458 | <1% | 365 | $376K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,508 | $366K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,068 | $363K |
| 76830 | Ultrasound, transvaginal | <1% | 3,454 | $348K |
| 62323 | <1% | 1,222 | $343K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,439 | $295K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 353 | $294K |
| G0378 | Hospital observation service, per hour | <1% | 12,132 | $289K |
| 96367 | <1% | 3,939 | $274K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,063 | $268K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,898 | $266K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,764 | $264K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,483 | $250K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,894 | $246K |
| 72100 | <1% | 3,470 | $244K | |
| 93971 | <1% | 1,718 | $243K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,553 | $241K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,470 | $239K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,517 | $234K |
| 96376 | <1% | 6,675 | $232K | |
| 80061 | Lipid panel | <1% | 21,931 | $224K |
| 93017 | <1% | 1,670 | $219K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,214 | $217K |
| 74150 | <1% | 1,431 | $217K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,743 | $204K |
| 76536 | <1% | 1,308 | $198K | |
| 72131 | <1% | 1,633 | $190K | |
| 72141 | <1% | 1,101 | $189K | |
| 80050 | General health panel | <1% | 6,693 | $188K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,170 | $185K |
| 73030 | <1% | 2,978 | $166K | |
| 93880 | <1% | 1,393 | $166K | |
| 73630 | <1% | 3,025 | $155K | |
| 64615 | <1% | 1,794 | $154K | |
| 74018 | <1% | 3,710 | $152K | |
| 73610 | <1% | 2,597 | $150K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 545 | $146K |
| 95886 | <1% | 2,436 | $139K | |
| 76770 | <1% | 976 | $139K | |
| 72040 | <1% | 2,064 | $138K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,899 | $132K |
| 76642 | <1% | 1,940 | $131K | |
| C1769 | Guide wire | <1% | 4,939 | $130K |
| 93923 | <1% | 1,511 | $128K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,496 | $127K |
| 70486 | <1% | 938 | $126K | |
| 74178 | <1% | 735 | $122K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,697 | $122K |
| 95800 | <1% | 1,339 | $119K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,282 | $115K |
| 73130 | <1% | 2,281 | $114K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,375 | $113K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,418 | $107K |
| 95811 | <1% | 147 | $106K | |
| 71250 | <1% | 1,101 | $105K | |
| 80081 | <1% | 1,993 | $101K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,857 | $101K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,650 | $92K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,158 | $92K |
| 76801 | <1% | 754 | $90K | |
| 84439 | <1% | 12,392 | $89K | |
| 96417 | <1% | 1,181 | $88K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,144 | $87K |
| 88342 | <1% | 1,645 | $83K | |
| 82607 | <1% | 7,040 | $81K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,706 | $81K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 291 | $81K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,422 | $81K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,766 | $80K |
| 64405 | <1% | 421 | $77K | |
| 93350 | <1% | 368 | $77K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,025 | $77K |
| 85027 | <1% | 14,990 | $76K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 644 | $76K |
| 97162 | <1% | 1,407 | $76K | |
| 73560 | <1% | 2,634 | $75K | |
| 83880 | <1% | 4,467 | $73K | |
| 95911 | <1% | 314 | $72K | |
| 73110 | <1% | 1,446 | $71K | |
| 95909 | <1% | 473 | $70K | |
| 84484 | <1% | 13,960 | $70K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,747 | $70K |
| 78227 | <1% | 243 | $68K | |
| 87507 | <1% | 337 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,328 | $66K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,152 | $65K |
| 86900 | <1% | 6,372 | $63K | |
| 88304 | <1% | 2,207 | $62K | |
| 84403 | <1% | 2,956 | $62K | |
| 73562 | <1% | 1,159 | $61K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 581 | $60K |
| 99152 | <1% | 1,269 | $58K | |
| 87806 | <1% | 2,472 | $57K | |
| 73502 | <1% | 1,659 | $56K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,672 | $56K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 265 | $55K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,035 | $54K |
| 84703 | <1% | 14,859 | $54K | |
| 82947 | <1% | 5,276 | $53K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,889 | $52K |
| 47562 | <1% | 14 | $52K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,904 | $51K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,149 | $49K |
| 84702 | <1% | 4,816 | $49K | |
| 59025 | Fetal non-stress test | <1% | 404 | $45K |
| 77065 | Tomosynthesis, mammo | <1% | 864 | $45K |
| 83690 | <1% | 13,630 | $44K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 296 | $44K |
| J3490 | Unclassified drugs | <1% | 3,196 | $44K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,841 | $44K |
| 72110 | <1% | 375 | $41K | |
| 87070 | <1% | 6,043 | $37K | |
| 74022 | <1% | 478 | $37K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,022 | $37K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 971 | $36K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 173 | $35K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,775 | $35K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,623 | $35K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,677 | $34K |
| 81001 | <1% | 19,505 | $34K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,865 | $34K |
| 86850 | <1% | 3,906 | $33K | |
| 82728 | <1% | 3,232 | $33K | |
| 87186 | <1% | 5,838 | $32K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,356 | $32K |
| 86803 | <1% | 3,014 | $31K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,585 | $31K |
| 76942 | <1% | 485 | $31K | |
| 84144 | <1% | 1,815 | $30K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,720 | $30K |
| 82565 | <1% | 2,225 | $30K | |
| 96523 | <1% | 1,150 | $30K | |
| 73590 | <1% | 399 | $29K | |
| 85610 | <1% | 10,317 | $29K | |
| 82077 | <1% | 3,808 | $28K | |
| 83735 | <1% | 8,001 | $27K | |
| 88142 | <1% | 1,520 | $27K | |
| 73221 | <1% | 147 | $27K | |
| 96415 | <1% | 429 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,432 | $25K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,520 | $25K |
| 87081 | <1% | 5,937 | $24K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,137 | $24K |
| 82746 | <1% | 2,267 | $24K | |
| 87653 | <1% | 1,006 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 45 | $23K |
| 12001 | <1% | 215 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,533 | $23K |
| 72072 | <1% | 364 | $23K | |
| 70496 | <1% | 118 | $23K | |
| 82570 | <1% | 6,068 | $22K | |
| 87077 | <1% | 4,272 | $22K | |
| 83001 | <1% | 1,428 | $22K | |
| 83550 | <1% | 3,243 | $21K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 124 | $21K |
| 81003 | <1% | 14,523 | $21K | |
| 82043 | <1% | 4,851 | $21K | |
| 27096 | <1% | 122 | $21K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,224 | $20K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,725 | $20K |
| 84146 | <1% | 1,303 | $20K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 243 | $19K |
| 83605 | <1% | 4,127 | $19K | |
| 83540 | <1% | 3,878 | $19K | |
| 88720 | <1% | 3,311 | $19K | |
| 82948 | <1% | 3,330 | $18K | |
| 93970 | <1% | 99 | $18K | |
| 86140 | <1% | 5,134 | $18K | |
| 86694 | <1% | 967 | $18K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 72 | $18K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,577 | $18K |
| 85730 | <1% | 5,590 | $17K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 57 | $17K |
| 80074 | <1% | 525 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,707 | $17K |
| 77066 | Tomosynthesis, mammo | <1% | 251 | $17K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 249 | $17K |
| 00731 | <1% | 354 | $17K | |
| 94060 | <1% | 257 | $17K | |
| 86901 | <1% | 4,139 | $17K | |
| 86787 | <1% | 2,013 | $17K | |
| 87040 | <1% | 3,663 | $17K | |
| 86038 | <1% | 1,811 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,689 | $16K |
| 73521 | <1% | 210 | $16K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 302 | $15K |
| 82962 | <1% | 3,288 | $15K | |
| 84270 | <1% | 864 | $15K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,833 | $15K |
| 84153 | <1% | 1,187 | $15K | |
| 93246 | <1% | 667 | $15K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 223 | $15K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,832 | $15K |
| 77080 | <1% | 505 | $14K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 798 | $14K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 26 | $14K |
| 71271 | <1% | 374 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,738 | $14K |
| 85379 | <1% | 3,291 | $14K | |
| 82670 | <1% | 567 | $13K | |
| 00840 | <1% | 137 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 186 | $13K |
| 72128 | <1% | 91 | $13K | |
| 83970 | <1% | 463 | $12K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 224 | $12K |
| 70491 | <1% | 73 | $12K | |
| 80306 | <1% | 1,561 | $11K | |
| 83002 | <1% | 700 | $11K | |
| 85652 | <1% | 5,071 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,683 | $11K |
| 94760 | <1% | 1,694 | $10K | |
| 87641 | <1% | 608 | $10K | |
| 80076 | <1% | 1,534 | $10K | |
| 81025 | <1% | 1,533 | $9K | |
| 80143 | <1% | 1,173 | $9K | |
| 80179 | <1% | 1,101 | $9K | |
| 73090 | <1% | 197 | $9K | |
| 97161 | <1% | 313 | $9K | |
| 80354 | <1% | 1,141 | $9K | |
| 10060 | <1% | 63 | $8K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,866 | $8K |
| S9443 | Lactation classes, non-physician provider, per session | <1% | 501 | $8K |
| 86431 | <1% | 1,686 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,502 | $8K |
| 82803 | <1% | 800 | $8K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 279 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 78 | $8K |
| 87205 | <1% | 2,628 | $7K | |
| 82950 | <1% | 1,995 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,271 | $7K |
| 00813 | <1% | 134 | $7K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 352 | $7K |
| 84550 | <1% | 2,000 | $7K | |
| 87075 | <1% | 1,272 | $7K | |
| 82150 | <1% | 1,585 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 190 | $7K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,060 | $7K |
| 94664 | <1% | 551 | $7K | |
| 70498 | <1% | 41 | $7K | |
| 73080 | <1% | 130 | $6K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 366 | $6K |
| 93356 | <1% | 144 | $6K | |
| 88307 | <1% | 143 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 142 | $6K |
| 93225 | <1% | 69 | $6K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 431 | $6K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 688 | $6K |
| 83525 | <1% | 592 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,988 | $6K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 23 | $6K |
| 97014 | <1% | 233 | $5K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 428 | $5K |
| 83516 | <1% | 356 | $5K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 363 | $5K |
| 90715 | <1% | 1,086 | $5K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 197 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 741 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,522 | $5K |
| 86592 | <1% | 1,423 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,167 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,078 | $5K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 43 | $5K |
| 82550 | <1% | 1,440 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 21 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $5K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 106 | $5K |
| 86696 | <1% | 328 | $4K | |
| 36600 | <1% | 703 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,326 | $4K |
| 88312 | <1% | 207 | $4K | |
| 84156 | <1% | 1,427 | $4K | |
| 86701 | <1% | 439 | $4K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 210 | $4K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,015 | $4K |
| 62321 | <1% | 14 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 994 | $4K |
| 84100 | <1% | 1,417 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,887 | $4K |
| 95816 | <1% | 29 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,634 | $4K |
| 87185 | <1% | 763 | $3K | |
| 76870 | <1% | 58 | $3K | |
| 86695 | <1% | 341 | $3K | |
| 81514 | <1% | 42 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 216 | $3K |
| 64493 | <1% | 19 | $3K | |
| 80164 | <1% | 394 | $3K | |
| 94729 | <1% | 127 | $3K | |
| C1776 | Joint device (implantable) | <1% | 14 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 236 | $3K |
| 87420 | <1% | 329 | $3K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 281 | $3K |
| 82378 | <1% | 213 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 123 | $3K |
| 95813 | <1% | 13 | $3K | |
| 72146 | <1% | 15 | $3K | |
| 00790 | <1% | 44 | $3K | |
| 93229 | <1% | 39 | $2K | |
| 84402 | <1% | 130 | $2K | |
| 12002 | <1% | 17 | $2K | |
| 71101 | <1% | 65 | $2K | |
| 93226 | <1% | 37 | $2K | |
| 87210 | <1% | 765 | $2K | |
| 86308 | <1% | 452 | $2K | |
| 00400 | <1% | 16 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 49 | $2K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 342 | $2K |
| 84132 | <1% | 838 | $2K | |
| 83615 | <1% | 270 | $2K | |
| 70544 | <1% | 12 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 710 | $2K |
| 82784 | <1% | 269 | $2K | |
| 73140 | <1% | 30 | $2K | |
| 80320 | <1% | 960 | $2K | |
| 12011 | <1% | 13 | $1K | |
| 84165 | <1% | 204 | $1K | |
| 94726 | <1% | 58 | $1K | |
| 64494 | <1% | 19 | $1K | |
| 84436 | <1% | 220 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 534 | $1K |
| 82248 | <1% | 360 | $1K | |
| C9399 | Unclassified drugs or biologicals | <1% | 94 | $1K |
| 20610 | <1% | 13 | $1K | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 107 | $1K |
| 71100 | <1% | 18 | $1K | |
| 80329 | <1% | 308 | $1K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 39 | $1K |
| 84145 | <1% | 72 | $1K | |
| 86003 | <1% | 13 | $1K | |
| 83655 | <1% | 97 | $948.71 | |
| 72120 | <1% | 33 | $937.42 | |
| 84112 | <1% | 13 | $912.42 | |
| 93922 | <1% | 18 | $907.34 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 97 | $865.24 |
| 86618 | <1% | 73 | $792.61 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 337 | $790.88 |
| 86757 | <1% | 49 | $766.26 | |
| 82533 | <1% | 60 | $734.97 | |
| 36591 | <1% | 50 | $721.61 | |
| 81002 | <1% | 283 | $712.00 | |
| 86617 | <1% | 28 | $707.91 | |
| 00812 | <1% | 18 | $658.91 | |
| 83721 | <1% | 166 | $642.87 | |
| 86403 | <1% | 77 | $626.84 | |
| 82140 | <1% | 80 | $563.77 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 203 | $553.30 |
| 97165 | <1% | 13 | $524.01 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 452 | $513.55 |
| 86376 | <1% | 33 | $449.61 | |
| 87045 | <1% | 46 | $436.58 | |
| 84481 | <1% | 29 | $426.84 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 785 | $418.34 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 107 | $396.69 |
| 96368 | <1% | 17 | $391.30 | |
| C1729 | Catheter, drainage | <1% | 61 | $385.51 |
| 87335 | <1% | 29 | $372.51 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 287 | $356.29 |
| 82247 | <1% | 97 | $355.26 | |
| 83883 | <1% | 31 | $350.88 | |
| 87046 | <1% | 46 | $341.22 | |
| 86334 | <1% | 27 | $332.83 | |
| 97116 | <1% | 53 | $316.52 | |
| 84155 | <1% | 204 | $315.06 | |
| 62369 | <1% | 28 | $314.08 | |
| 85014 | <1% | 236 | $300.08 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 46 | $262.39 |
| 94727 | <1% | 29 | $260.52 | |
| 87015 | <1% | 134 | $247.57 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 145 | $245.68 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 104 | $245.46 |
| 87324 | <1% | 32 | $234.93 | |
| 87899 | <1% | 36 | $230.65 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 198 | $217.54 |
| 36416 | <1% | 67 | $213.88 | |
| 83021 | <1% | 15 | $207.71 | |
| 86703 | <1% | 16 | $201.16 | |
| 85018 | <1% | 136 | $197.70 | |
| 82977 | <1% | 34 | $196.68 | |
| 31720 | <1% | 12 | $188.16 | |
| 86039 | <1% | 23 | $153.76 | |
| 82175 | <1% | 12 | $149.10 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 275 | $144.12 |
| 82785 | <1% | 14 | $136.63 | |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 32 | $129.65 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 62 | $127.55 |
| 87807 | <1% | 24 | $124.04 | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 14 | $115.61 |
| 83825 | <1% | 12 | $115.45 | |
| 87427 | <1% | 14 | $104.61 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 35 | $103.91 |
| 87340 | <1% | 15 | $99.81 | |
| 85045 | <1% | 32 | $91.38 | |
| 87449 | <1% | 17 | $87.17 | |
| 64447 | <1% | 13 | $70.98 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 12 | $69.31 |
| A4364 | Adhesive, liquid or equal, any type, per oz | <1% | 13 | $67.34 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 268 | $66.24 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 14 | $64.81 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 20 | $59.24 |
| 89050 | <1% | 17 | $35.56 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 17 | $33.22 |
| 81015 | <1% | 20 | $31.72 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 27 | $26.40 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 18 | $21.12 |
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | <1% | 22 | $19.50 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 19 | $19.41 |
| A4217 | Sterile water/saline, 500 ml | <1% | 22 | $12.80 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 29 | $10.48 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 64 | $0.29 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 21 | $0.17 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 203 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 93 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYUNGMANN, MICHAEL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Lourdes Ambulatory Surgery Center LLC | Paducah, KY | $596K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.